Teva Pharmaceuticals USA is recalling 313 bottles of Clozapine Orally Disintegrating Tablets (12.5 mg) because the tablets did not break down correctly during routine quality testing. When tablets do not disintegrate as required, they may not provide the intended dose of medication or may be difficult to swallow. The affected products are 100-count bottles containing yellow, round tablets marked with the number '13'. This recall was initiated after stability testing showed the drug was not meeting performance specifications.
The tablets may fail to dissolve properly in the mouth, which can lead to improper absorption of the medication and reduced effectiveness in treating underlying conditions. There is also a potential risk for patients who have difficulty swallowing if the tablet remains solid longer than expected.
Refund and clinical guidance.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.